Here’s the latest instalment in our news updates from Blackford Platform Partners.
Lung disease detection AI company Riverain Technologies has created a useful resource page for anyone interested in starting or improving a lung screening program.
Intelligent oncology software developer Aidence announced it has been acquired by US diagnostic imaging services provider RadNet, which has now secured effective screening solutions for two of the top four most prevalent cancers. Aidence also published an article on quality assurance in lung cancer screening, building on the company’s experience with NHS England’s Targeted Lung Health Checks.
X-ray AI company Gleamer published a new scientific paper in the journal Radiology, which assesses the effect of AI assistance on the diagnostic performance of physicians when detecting fractures on radiographs. A video summary of the paper was also released.
Lung analysis firm VIDA announced a new upcoming webinar taking place today, 10th February 2022 at 1pm CST, entitled “Protecting Our Lungs in 2022 and Beyond.” Featuring Dr Meilan Han, Chief of Pulmonary & Critical Care Medicine at the University of Michigan, the webinar will explore strategies to protect lung health from the risks the respiratory system faces from viruses like SARS-CoV-2, smoking, vaping, pollution and more. It will be recorded and posted here a few days after it took place.
Neuroimaging AI company Cercare Medical has signed a contract with Karolinska University Hospital to use Cercare Perfusion, for brain CT and MRI assessment. The hospital will now use the innovative perfusion imaging solution to assess all brain perfusion scans ranging from traditional applications to cutting-edge research including analysis of long COVID-19 symptoms.
Medical AI provider InferVision announced the completion of its Series D2 financing round, led by Goldman Sachs Asset Management, and bringing the total raised in both Series D rounds to $140 million.
In addition to its CT Lung AI product, the company’s InferRead CT Stroke AI is now also FDA cleared for use in the US, and InferVision is also joining efforts to end TB with AI by participating in a webinar on X-ray TB detection solutions, organized by the Stop TB Partnership.
Imaging AI specialist icometrix announced its selection as a new data partner in the European Health Data and Evidence Network project (EHDEN), a public-private partnership set up to address the current challenges in generating insights and evidence from real-world clinical data at scale.
icometrix also published a new study, which suggests that neurodegeneration in MS can slow down to the rate of normal aging once inflammatory disease activity has been extinguished, and contributed an article to Applied Radiology on the hopeful role of imaging AI in the fight against Alzheimer’s.
And finally, AI-powered breast health solution provider Densitas published a new Leaders in Breast Health interview with Dr. Georgia Spear, Chief of Breast Imaging at NorthShore University HealthSystem. The interview covers the impact of COVID-19 on her practice in the early stages of the pandemic, and her perspective on the potential values of AI in breast screening.
Stay tuned for more partner news next month!